AN2 Therapeutics, Inc.: Coastlands Capital LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Coastlands Capital LP amended its Schedule 13G filing on AN2 Therapeutics, Inc., updating its beneficial ownership stake with the SEC under accession number 0001104659-26-127408. The filing, submitted via the SEC's EDGAR system, reflects a change to the investor's previously reported position in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically filed by passive investors when their ownership crosses or adjusts relative to the 5% threshold, though the headline did not disclose the specific percentage or share count. The update matters because it signals a shift in institutional ownership for AN2 Therapeutics, a company whose shares are sensitive to pipeline developments and investor confidence. What to watch next is the full filing detail, which should clarify whether Coastlands increased, trimmed, or maintained its stake and whether the change reflects passive rebalancing or a more deliberate position shift.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
AN2 Therapeutics, Inc., Coastlands Capital LP